Renergen is proud to announce the completion and successful operation of the Company's first Cryo-VaccTM prototype, which is being presented to South African based media at its headquarters in Johannesburg, on February 15, 2021 at 10am SAST. Cryo-Vacc was designed and patented by Renergen for efficient transport and storage of ultra-cold biologics for periods of up to 25 days or longer in transit, where access to an external power source is not possible. The Cryo-Vacc has a temperature range of -150 ºC to 8ºC, making it highly versatile for a range of vaccines. Combined with best-in-class cold chain monitoring and asset tracking technology from Beyond Wireless Proprietary Limited (Beyond), a World Health Organisation Performance, Quality and Safety (PQS) certified remote temperature monitoring solution provider, the Cryo-Vacc can provide accurate temperature readings of the vaccines whilst in transit, as well as GPS tracking to ensure the custody chain can be audited. Beyond is an Internet of Things (IoT) solutions provider, specialising in remote temperature monitoring and control, with a specific focus on the global public healthcare sector. Beyond has active deployments in over 70 countries and are proud to partner with numerous for-profit enterprises, Ministries of Health, as well as several non-governmental organizations including UNICEF, the World Health Organisation, the International Committee for the Red Cross, and the Pan American Health Organisation. Cryo-Vacc is ideal for both air and ground transportation, utilising liquid nitrogen to transport by road and helium to transport by air. Aside from helium being only a fraction of the weight of nitrogen, significantly reducing its cost in airfreight, when used in Cryo-VaccTM helium can accommodate up to 12 times more vials per flight compared to other cryogens based on current flight safety regulations.